<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Algorithm for management of ileocolonic Crohn disease in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Algorithm for management of ileocolonic Crohn disease in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Algorithm for management of ileocolonic Crohn disease in children</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm depicts a range of reasonable practice. Treatment decisions for individual patients typically depend upon a variety of factors, including patient and family preference, response to prior regimens, clinician experience with a particular approach, and institutional resources.</div><div class="graphic_footnotes">EEN: exclusive enteral nutrition; 

	anti-TNF: anti-tumor necrosis factor; 

	IFX: infliximab; 

	6-MP: 6-mercaptopurine; 

	AZA: azathioprine; 

	MTX: methotrexate; 

	PEN: partial enteral nutrition; 

	ESR: erythrocyte sedimentation rate; 

	CRP: C-reactive protein.<br/>	

	* Preliminary studies suggest that PEN with a specific exclusion diet may be as effective and better accepted by patients than EEN<sup>[1]</sup>.<br/>	

	¶ For patients with severe disease, enteral nutrition therapy might be used in combination with glucocorticoids or other medical treatments for induction of remission.<br/>	

	Δ Although aminosalicylates are attractive because of low toxicity, it is unclear if these drugs are superior to placebo in preventing relapse. As a result, immunomodulators (6-MP/AZA or MTX) or anti-TNF antibodies are generally used for maintenance therapy for patients with moderate or severe disease.<br/>
<span class="lozenge">◊</span> Many clinicians prefer to avoid thiopurines (6-MP/AZA) because of the slight increase in absolute risk for lymphoma and nonmelanoma skin cancers. The debate continues on the benefit-to-risk ratio of thiopurines. MTX or early use of anti-TNF therapies are increasingly being utilized as alternatives.<br/>	

	§ Early use of anti-TNF antibodies (ie, for initial induction or first step in maintenance) is a reasonable option for patients with moderate to severe CD. This is especially appropriate for patients with the following characteristics, which suggest high risk for complicated disease<sup>[2-4]</sup>:

	<ul>
<li>Severe perianal disease</li>
<li>Steroid-unresponsive</li>
<li>Deep fissuring ulcers in the colon</li>
<li>Extensive disease involving the mid-small bowel</li>
<li>Growth failure (if severe and/or occurring in late puberty)</li>
</ul>

	

	¥ Relapse may include clinical symptoms of Crohn disease or other evidence of persistent disease activity including laboratory evidence of persistent inflammation (elevated ESR or CRP) or findings from endoscopy or imaging.<br/>	

	‡ In general, patients requiring more than 1 course of glucocorticoids within 1 year should be advanced to a different immunomodulator or to an anti-TNF antibody.</div><div class="graphic_reference">References:

<ol>
<li>Levine A, Wine E, Assa A, et al. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology 2019; 157:440.</li>
<li>Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146:383.</li>
<li>Turner D, Griffiths AM, Veereman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013; 11:1480.</li>
<li>Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014.</li>
</ol></div><div id="graphicVersion">Graphic 64031 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
